|(19)||(11)||EP 2 716 284 A3|
|(12)||EUROPEAN PATENT APPLICATION|
|(88)||Date of publication A3: |
|05.11.2014 Bulletin 2014/45|
|(43)||Date of publication A2: |
|09.04.2014 Bulletin 2014/15|
|(22)||Date of filing: 28.05.2004|
|(51)||International Patent Classification (IPC): |
|(84)||Designated Contracting States: |
|AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|(30)||Priority: ||28.05.2003 US 473902 P|
|(62)||Application number of the earlier application in accordance with Art. 76 EPC: |
|04753818.6 / 1663178|
|(71)||Applicant: MonoSol RX LLC|
|Portage IN 46368 (US)|
- Yang, Robert K.
Henderson, Nevada 89052 (US)
- Fuisz, Richard C.
Beverly Hills, CA California CA 90210 (US)
- Myers, Gary L.
Kingsport, TN Tennessee 37660-2936 (US)
- Fuisz, Joseph M.
Bay Harbor Island, FL Florida FL 33154-1204 (US)
|(74)||Representative: EP&C |
|P.O. Box 3241|
2280 GE Rijswijk
2280 GE Rijswijk (NL)
| || |
|(54)||Polyethylene oxide-based films and drug delivery systems made herefrom|(57)
The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.